These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 27802526)

  • 1. First DMD Drug Gains Approval.
    Voelker R
    JAMA; 2016 Nov; 316(17):1756. PubMed ID: 27802526
    [No Abstract]   [Full Text] [Related]  

  • 2. [Genetic Diagnosis and Molecular Therapies for Duchenne Muscular Dystrophy].
    Takeshima Y
    Rinsho Byori; 2015 Oct; 63(10):1194-201. PubMed ID: 26897856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Anesthetic complications. The incidence of severe anesthetic complications in patients and families with progressive muscular dystrophy of the Duchenne and Becker types].
    Breucking E; Reimnitz P; Schara U; Mortier W
    Anaesthesist; 2000 Mar; 49(3):187-95. PubMed ID: 10788987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, tissue distribution and excretion of a new photodynamic drug deuxemether.
    Wang R; Hao H; Wang G; Xie H; Xu M; Wang W; He H; Li X
    J Photochem Photobiol B; 2008 Mar; 90(3):179-86. PubMed ID: 18267365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New drug for severe pain gains approval.
    Health News; 2005 Mar; 11(3):2. PubMed ID: 15818782
    [No Abstract]   [Full Text] [Related]  

  • 6. Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response.
    Río J; Tintoré M; Sastre-Garriga J; Nos C; Castilló J; Tur C; Comabella M; Montalban X
    Eur J Neurol; 2012 Jun; 19(6):899-904. PubMed ID: 22289050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An overview of randomized clinical trials in metastatic breast cancer: variables affecting regulatory drug approval.
    Conde-Estévez D; Tusquets I; Servitja S; Martínez-García M; Salas E; Albanell J
    Anticancer Drugs; 2014 Oct; 25(9):992-7. PubMed ID: 24892723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patent battle lines drawn as sofosbuvir gains approval.
    Harrison C
    Nat Rev Drug Discov; 2014 Jan; 13(1):12. PubMed ID: 24378791
    [No Abstract]   [Full Text] [Related]  

  • 9. Early pathogenesis of Duchenne muscular dystrophy modelled in patient-derived human induced pluripotent stem cells.
    Shoji E; Sakurai H; Nishino T; Nakahata T; Heike T; Awaya T; Fujii N; Manabe Y; Matsuo M; Sehara-Fujisawa A
    Sci Rep; 2015 Aug; 5():12831. PubMed ID: 26290039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. With a favorable side effect profile, Tecfidera gains the FDA's approval.
    Morrow T
    Manag Care; 2013 Jun; 22(6):59-60. PubMed ID: 23837293
    [No Abstract]   [Full Text] [Related]  

  • 11. Naloxone auto-injector gains FDA approval.
    Knopf A
    Behav Healthc; 2014; 34(3):48-9. PubMed ID: 25065155
    [No Abstract]   [Full Text] [Related]  

  • 12. Descemet's membrane detachment in horses; case series and literature review.
    Matas Riera M; Donaldson D; Priestnall SL
    Vet Ophthalmol; 2015 Sep; 18(5):357-63. PubMed ID: 25180582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P2RX7 purinoceptor: a therapeutic target for ameliorating the symptoms of duchenne muscular dystrophy.
    Sinadinos A; Young CN; Al-Khalidi R; Teti A; Kalinski P; Mohamad S; Floriot L; Henry T; Tozzi G; Jiang T; Wurtz O; Lefebvre A; Shugay M; Tong J; Vaudry D; Arkle S; doRego JC; Górecki DC
    PLoS Med; 2015 Oct; 12(10):e1001888. PubMed ID: 26461208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural characterizations of phage antitoxin Dmd and its interactions with bacterial toxin RnlA.
    Wei Y; Gao Z; Zhang H; Dong Y
    Biochem Biophys Res Commun; 2016 Apr; 472(4):592-7. PubMed ID: 26972252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perinatal outcomes in women with multiple sclerosis exposed to disease-modifying drugs.
    Lu E; Dahlgren L; Sadovnick A; Sayao A; Synnes A; Tremlett H
    Mult Scler; 2012 Apr; 18(4):460-7. PubMed ID: 21914689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rocuronium 0.3 mg x kg-1 (ED95) induces a normal peak effect but an altered time course of neuromuscular block in patients with Duchenne's muscular dystrophy.
    Muenster T; Schmidt J; Wick S; Forst J; Schmitt HJ
    Paediatr Anaesth; 2006 Aug; 16(8):840-5. PubMed ID: 16884467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prostaglandin D2 metabolite is elevated in the urine of Duchenne muscular dystrophy patients and increases further from 8 years old.
    Nakagawa T; Takeuchi A; Kakiuchi R; Lee T; Yagi M; Awano H; Iijima K; Takeshima Y; Urade Y; Matsuo M
    Clin Chim Acta; 2013 Aug; 423():10-4. PubMed ID: 23603101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pediatric drug development programs for type 2 diabetes: A review.
    Christensen ML; Franklin BE; Momper JD; Reed MD
    J Clin Pharmacol; 2015 Jul; 55(7):731-8. PubMed ID: 25781151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [c.2381-3T>C mutation of DMD gene: a rare SNP without significant pathogenicity].
    Yan Y; Yang Y
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2015 Feb; 32(1):77-80. PubMed ID: 25636106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trials to address efficacy of midodrine 18 years after it gains FDA approval.
    Mitka M
    JAMA; 2012 Mar; 307(11):1124, 1127. PubMed ID: 22436941
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.